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A B S T R A C T
Current evidence from several clinical trials indicates that primary angioplasty in pa-
tients with acute myocardial infarction (AMI) appears superior reperfusion therapy 
to immediate thrombolysis, even when transfer to an angioplasty center is necessary. 
Thus, organization of ambulance systems and adequate angioplasty facilities appears 
to be the key issue in providing the most effective contemporary reperfusion therapy 
for AMI. Furthermore, on-site primary coronary angioplasty in high-risk AMI pa-
tients at hospitals with no cardiac surgery on-site is nowdays considered safe, effective, 
and faster than angioplasty after transfer to a surgical facility.
Randomized trials have demonstrated the superiority of primary angioplasty with 
stent implantation over balloon angioplasty alone in the treatment of AMI, includ-
ing patients with diabetes. Stent use has been associated with significant decreases in 
length of stay, major adverse cardiovascular events, and in-hospital mortality. Finally, 
because of the risk of stent thrombosis, the issue of whether drug-eluting stents are 
safe or even more beneficial than bare-metal stents in patients with AMI, as in other 
non-AMI patient groups, remains uncertain, although preliminary data seem to fa-
vour the use of drug-eluting stents.
I N T R O D U C T I O N
Acute myocardial infarction (AMI) has been associated with thrombotic occlu-
sion of a coronary artery as early as in 1793 when an autopsy was performed on Sir 
James Hunter, a famous surgeon who died suddenly following a violent argument 
with hospital administrators in London.1 The term “acute coronary thrombosis” was 
well established in medical literature and its connotation was reaffirmed following 
the seminal study of DeWood et al in 1980.2 Thrombolytic agents were discovered 
in the 1950s and, following long debates about their clinical benefits,3 they entered 
clinical routine in 1986.4
However, it is now evident that although fresh thrombus represents the major 
pathological finding in acutely occluded coronary arteries, it is found in less than 
70% of the cases.5-7 This is in keeping with the current success rates of thrombolytic 
trials that, even with the use of aggressive protocols, result in restoration of normal 
coronary flow (TIMI 3) in only 60 to 70% of the cases.8 It seems that a considerable 
proportion of AMI might be due to spontaneous dissection and/or severe intramural 
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hemorrhage and extensive plaque rapture, in the context of 
preexisting atheromatosis. We know now that although soft, 
noncritical lesions are more prone to rapture and consequent 
acute thrombotic occlusion, rapid stenosis progression is not 
uncommon and complex stenoses are at risk more than smooth 
lesions to evolve into coronary occlusions.9 Resolution of any 
overlying thrombus by thrombolytic agents in this respect is 
unlikely to restore adequate antegrade flow in the coronary 
artery. Mechanical reperfusion, therefore, appears to be 
necessary in at least a proportion of patients with AMI and 
these patients cannot be identified in advance.
Furthermore, the incidence of intracranial hemorrhage 
following thrombolysis is estimated between 0.26 to 2.17% 
depending on preexisting risk factors.10 Thus, certain patient 
groups such as the elderly (>65 years), women, hypertensive 
patients and diabetics are at an increased risk of intracranial 
hemorrhage when subjected to thrombolysis. It has been 
shown that over 95% of patients presenting with AMI are ac-
ceptable candidates for primary angioplasty (PTCA), whereas 
up to 1/3 of cases are considered to have contraindications to 
thrombolysis.11 Several patients are therefore being denied 
the benefits of revascularization in this respect and the pos-
sibility of direct revascularization seems to be a reasonable 
alternative.
P R I m A R y  P T C A  v S  T h R O m B O ly S I S
Since the first reported cases of primary angioplasty in 
1983,12 several thousands of patients have been enrolled in 
randomised trials comparing the interventional approach 
with thrombolysis. It is now clear that primary angioplasty 
performed in experienced centers offers higher patency rates 
of the infarcted vessel (85-90% at 90 minutes), decreased 
cost and length of hospital stay, lower stroke and recurrent 
infarction rates and lower 30-day and 6-month mortality as 
compared to thrombolytic therapy.13-18 In an early meta-analy-
sis of 10 trials, primary angioplasty achieved a 35% decrease 
in mortality compared with thrombolytic therapy alone.19 
Mechanical recanalization avoids the interstitial edema, 
contraction band necrosis and microvascular hemorrhage 
seen with thrombolysis.8 Early patency of the occluded artery 
is higher with decreased reocclusion rate and collateral flow 
to non-infarct-related myocardium is probably increased, 
thus allowing better healing of the infarcted area and less 
ventricular dilatation.18-20 All these may well translate into an 
improved short-term outcome as well as long-term survival. 
WC Robert’s admonition, therefore, “when I have an acute 
myocardial infarction take me to the hospital that has a cardiac 
catheterization laboratory and open cardiac surgical facili-
ties” stated >20 years ago,20 seems to be absolutely justified 
nowadays and if anything is to be argued this is only the need 
for surgical support.
P R E R E q U I S I T I E S  f O R  I N T E R v E N T I O N
While thrombolysis is a relatively simple therapeutic pro-
cedure available even in primary care settings, PTCA requires 
the availability of institutions with cardiac catheterization 
facilities. Timely admission of the patient to such a unit is not 
always possible and the time to treatment with primary PTCA, 
as with thrombolytic therapy, is a critical determinant of mor-
tality.21,22 In the GUSTO IIb trial the 30-day mortality rate of 
patients who underwent balloon inflation within 60 minutes 
after study enrolment was 1.0%, but beyond 90 minutes after 
enrolment, 6.4%.23 It is now accepted that, although either 
fibrinolysis or PTCA can be considered within the first 12 
hours from the onset of symptoms, the time interval for the 
implementation of primary PTCA should not exceed 2 hours 
after the diagnosis of AMI.24
Primary PTCA also requires skilled operators performing 
at least 75 procedures per year.25,26 In busy centers absolute 
case volumes may not be as important but institutional experi-
ence, in general, influences complication rates and procedural 
outcomes.27,28 The issue of cardiac surgical back-up is cur-
rently under investigation. Although the ACC/AHA guidelines 
recommend standby facilities, evidence is accumulating that 
surgical coverage may not be necessary.29-31
A N g I O P l A S T y  D E v I C E S  A N D  A D j U N C T I v E 
P h A R m A C O T h E R A P y
Aspirin and heparin (unfractionated or low molecular 
weight) should be given to all patients undergoing primary 
PTCA. A thienopyridine, such as clopidogrel, which appears 
to have a favourable safety profile should also be used regard-
less of the use of stents.32 These agents are also superior to 
antocoagulation with fewer cardiac events and less bleeding 
complications.33
Several randomised trials have reported on the impact of 
stent use in primary PTCA.34-41 There has been a tendency 
towards lower mortality with stenting, although not confirmed 
by all studies, and a significant reduction in the incidence of 
the subsequent target vessel revascularization (almost three-
fold) with stenting. In one of the larger of the trials (PAMI-
STENT)37 there was also a slightly lower rate of TIMI 3 flow 
with stenting, thus raising the possibility of distal embolization 
of thrombus protruding through the stent struts at the time of 
deployment. Direct stenting without predilation has been re-
ported to result in reduced microvascular injury and improved 
ST-segment resolution.42 The concomitant use of antiplatelet 
agents such as IIb/IIIa receptor blockers seems to reduce 
the incidence of this complication and several trials have ad-
dressed this issue.43-46,91 Results have shown better TIMI flows 
and reduced major adverse cardiac events at 6 months with 
the use of these agents, although restenosis rates were unaf-
fected. Improvement of peak flow velocity and regional wall 
motion in the infarct area have been demonstrated with the 
use of IIb/IIIa following primary stenting,47,91 and these find-
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ings did translate into a lower cumulative incidence of death, 
reinfarction, or stroke at 6 months as compared with throm-
bolysis alone.43 The ADMIRAL trial45 showed that initiation 
of abciximab before stenting resulted in improved TIMI flow 
immediately after the procedure and at 6 months. At 6-month 
follow-up, death rates were not different among groups but 
stents with IIbIIIa inhibitors offered the lowest ischemic target 
revascularization rate. The CADILLAC study46 randomized 
2082 patients with AMI to undergo PTCA alone, PTCA 
plus abciximab, stenting alone, or stenting plus abciximab. 
At six months, the primary end point - a composite of death, 
reinfarction, stroke, and revascularization of the target vessel 
– had occurred in 20% of patients after PTCA, 16.5% after 
PTCA plus abciximab, 11.5% after stenting, and 10.2% after 
stenting plus abciximab (P<0.001). However, there were no 
significant differences among the groups in the rates of death, 
stroke, or reinfarction; the difference in the incidence of the 
primary end point was due entirely to differences in the rates 
of target-vessel revascularization (ranging from 15.7% after 
PTCA to 5.2% after stenting plus abciximab). The rate of 
angiographically established restenosis was 40.8% after PTCA 
and 22.2% after stenting (P<0.001), and the respective rates 
of reocclusion of the infarcted-related artery were 11.3% and 
5.7% (P=0.01), both independent of abciximab use. A recent 
meta-analysis also confirmed that primary stenting is superior 
to balloon angioplasty in reducing target vessel revasculariza-
tion within the next year following AMI, although reinfarction 
or mortality rates were not affected.90
Several mechanical strategies have also been evalu-
ated in an effort to prevent microembolization and enhance 
myocardial perfusion. They include extraction atherectomy,48 
rheolytic atherectomy with the Angiojet device,49 ultrasound 
thrombolysis,50 thrombectomy with the X-sizer catheter,51 and 
filter protection with the Guardwire and the Filterwire.52,53
However, the administration of antiplatelet agents or 
mechanical filters may not be enough to prevent distal em-
bolization.54 Even the achievement of TIMI 3 flow does not 
necessarily imply optimal myocardial perfusion.55,56 Distal 
embolization with capillary plugging and microcirculatory 
injury and dysfunction may be caused by the AMI process.56,57 
Nevertheless, a recent meta-analysis of 21 randomized trials 
conducted with adjunctive mechanical devices to prevent distal 
embolization in 3721 patients with AMI, indicated that the use 
of adjunctive mechanical devices to prevent distal emboliza-
tion is associated with better myocardial perfusion and less 
distal embolization, but without an apparent improvement 
in survival.58
C O S T
Several analyses have found primary PTCA not to be more 
expensive than the conservative strategy using thrombolysis.59-61 
Actually primary angioplasty may reduce costs by offering 
lower readmission rates and shorter hospital stay.62
S P E C I f I C  C l I N I C A l  S E T T I N g S
Elderly patients, especially >75 years old, have an in-
creased mortality after AMI and thrombolytic therapy may 
be of limited value in this setting.63,64 For patients 65 to 75 
years old, thrombolytic therapy has been associated with a 
survival benefit, whereas among patients aged 76 to 86 years, 
it has been actually associated with a survival disadvantage.47 
Primary PTCA appears to have a particular advantage over 
thrombolysis for the management of AMI in the elderly 
and this has been a consistent finding in the initial primary 
angioplasty trials. Nevertheless, elderly patients undergoing 
primary revascularization have a higher complication and 
mortality rate than their younger counterparts.65,66
Diabetics also appear to have a considerably better out-
come with intervention rather than thrombolysis.8,28 Other 
situations in which thrombolysis is relatively less effective is 
congestive heart failure67 and occlusion of saphenous bypass 
grafts.68 Primary PTCA may also be beneficial in these pa-
tient cohorts69 although graft angioplasty is associated with 
relatively higher adverse event rates.70
The leading cause of death in patients hospitalized for 
AMI is cardiogenic shock and mortality rates ranges between 
60 to 90% without treatment. The impact of thrombolysis in 
this respect is doubtful4 and mortality still exceeds 65%. Suc-
cessful primary PTCA has been reported to reduce mortality 
rates to 30%.67 According to the SHOCK randomized trial,69 in 
patients with cardiogenic shock, emergency revascularization 
did not significantly reduce overall mortality at 30 days. This 
was also the case in the small, prematurely stopped SMASH 
trial.71 However, after 6 months there was a significant survival 
benefit in the SHOCK patients undergoing revascularization.69 
Prospective registries also suggest that early revascularization 
should be strongly considered for patients with acute myocar-
dial infarction complicated by cardiogenic shock.72
T h E  f U T U R E :  fA C I l I T A T E D  A N g I O P l A S T y
Although the majority of patients subjected to throm-
bolysis are found to have a significant residual stenosis,73 
routine empirical use of PTCA following thrombolysis has 
not been found beneficial in early trials; actually there was 
a trend towards increased mortality following intervention 
in this setting.74-77 Recent data, however, from contemporary 
trials in the era of stents and IIb/IIIa antagonists, suggest a 
probable benefit of rescue PTCA in several distinct scenarios 
and that the pivotal mid-1980s studies suggesting no benefit 
or harm for PTCA after fibrinolytic therapy may no longer 
be relevant.78-80,93 This is particularly true for cases of failed 
thrombolysis. The RESCUE trial investigating the impact of 
angioplasty in patients with anterior AMI and angiographi-
cally demonstrated coronary occlusion reported a reduction 
in the composite end point of death or congestive heart failure 
at 30 days post-PTCA.78 PTCA after failed fibrinolysis (TIMI 
0 to 1 flow) appears to significantly reduce early severe heart 
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failure (3.8% vs 11.7%) and improve survival over 1 year in 
patients with moderate to large AMI (92% vs 87%), and pos-
sibly reduce early repeat AMI (4.3% vs 11.3%). Similar trends 
were reported in other trials.81-83
More importantly, mechanical reperfusion in AMI has 
been found to result in better flow and outcome when per-
formed on open than occluded arteries. The combination of 
low dose thrombolysis with subsequent angioplasty has been 
addressed by the PACT trial.84 In this study, AMI patients 
subjected to rescue PTCA within one hour following half-
dose t-PA (50 mg bolus) did not display higher rates of stroke 
or bleeding complications as compared to those treated with 
PTCA without previous thrombolysis. Left ventricular func-
tion, however, was significantly better in patients achieving 
TIMI 3 flow by the time of angiography or when produced by 
angioplasty. Long-term follow-up studies have also indicated 
that when reperfusion occurs before primary angioplasty, 
outcomes are better with improved procedural outcomes, 
smaller infarct size, better preservation of left ventricular 
function, and reduced mortality.85 This has encouraged new 
strategies to establish reperfusion before primary angioplasty 
with platelet inhibitors and/or low-dose thrombolytic drugs. A 
combination of half dose thrombolysis with IIb/IIIa inhibitors 
in the GUSTO V trial86 did not demonstrate increased rates 
of intracranial hemorrhage or disabling stroke as compared 
with thrombolysis alone. There is evidence, however, that 
this combination might reduce angiographically evident 
thrombus in AMI.91 The SPEED trial87 studied 323 patients 
who underwent angioplasty with planned initial angiography 
63 min following thrombolysis or half dose reteplase com-
bined with IIb/IIIa inhibitors. Early angioplasty patients had 
fewer ischemic events and bleeding complications than did 
patients not undergoing early angioplasty. Patients receiv-
ing abciximab with reduced-dose reteplase showed an 86% 
incidence of TIMI grade 3 flow at approximately 90 min and 
a trend toward improved outcomes. The standard definition 
of TIMI flow grade 3 was used in this trial, however, instead 
of the “3 heart beat definition” for dye to traverse the artery 
that was adopted in other interventional trials.89 Should the 
same criteria have been used by the SPEED investigators, an 
approximately 96% TIMI 3 rate would have been expected.87 A 
retrospective analysis of the TIMI 14 data, also demonstrated 
greater ST-segment resolution following combination of low 
dose thrombolysis, IIb/IIIa antagonist and mechanical reper-
fusion, as compared to full-dose thrombolysis alone.92,93 Thus, 
both rescue angioplasty (artery closed before the procedure) 
and adjunctive angioplasty (artery open before the procedure) 
are beneficial in the setting of AMI.
This approach of facilitated angioplasty in order to reduce 
the time delay inherent with mechanical reperfusion is promis-
ing and is being currently studied in randomized trials. It is 
theoretically at least compatible with the “open vasculature” 
hypothesis which argues for the achievement of early flow, 
full microvascular flow, full epicardial flow, and sustained 
flow.89 It remains to be seen whether the higher efficacy can be 
combined with lower intracranial hemorrhage rates than those 
seen with ordinary thrombolysis. Recently, the CAPITAL 
AMI study showed that in patients presenting with high-risk 
STEMI, tenecteplase plus immediate angioplasty reduced the 
risk of recurrent ischemic events compared with tenecteplase 
alone and was not associated with an increase in major bleed-
ing complications.94
f I N A l  P E R S P E C T I v E
It is now abundantly clear that primary angioplasty in pa-
tients with AMI remains superior to immediate thrombolysis, 
even when transfer to an angioplasty center is necessary.95 
Organization of ambulance systems and adequate angioplasty 
facilities appear to be the key issues in providing the most 
effective reperfusion therapy for AMI. Furthermore, on-site 
primary angioplasty in high-risk AMI patients at hospitals 
with no cardiac surgery on-site is nowdays considered safe, 
effective, and faster than angioplasty after transfer to a sur-
gical facility; on-site angioplasty and transfer groups have 
reported to have similar 30-day outcomes and more rapid 
reperfusion.96
Randomized trials have demonstrated the superiority 
of primary angioplasty with stent implantation over balloon 
angioplasty alone in the treatment of AMI.97,98 Stent use has 
been associated with significant decreases in length of stay, 
major adverse cardiovascular events, and in-hospital mortal-
ity.95 Diabetics with AMI also benefit from this strategy with 
stent implantation,99 which significantly reduces restenosis 
and enhances survival free from target vessel revasculariza-
tion, independent of IIb/IIIa use; however, survival remains 
reduced compared with survival in nondiabetic patients 
regardless of reperfusion modality. Finally, because of the 
risk of stent thrombosis, the issue of whether drug-eluting 
stents are safe or even more beneficial than bare-metal stents 
in patients with AMI, as in other non-AMI patient groups, 
remains uncertain. Preliminary studies of use of drug-eluting 
stents comparing their results with use of bare-metal stents, 
indicate lower AMI and death rates in mid-term follow-up with 
drug-eluting stents.100 Further studies are needed to clarify 
this important issue.
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